Abstract
This article reviews the scientific development of angiomyogenesis using VEGF165-myoblasts, a patented biotechnology platform in regenerative medicine associated with Human Myoblast Genome Therapy (HMGT), also known as Myoblast Transfer Therapy (MTT). VEGF165-myoblasts are the leading biologics for angiomyogenesis. This review also compares the safety and efficacy of VEGF165-myoblasts transduced using adenoviral vectors, nanoparticles or liposomes, in anticipation of their application in clinical trials in the near future. VEGF165-myoblasts are differentiated myogenic cells capable of extensive division, natural cell fusion, nucleus transfer, cell therapy and genome therapy. Following transplantation they survive, develop and function to revitalize degenerative myocardium in heart failure and ischemic cardiomyopathy animal studies. VEGF165-myoblasts are second generation products of HMGT/MTT which replenishes live cells and genetically repairs degenerating myofibers in Type II diabetes, muscular dystrophies, aging dysfunction and disfigurement. Myoblasts have also been used to enhance skin and muscle appearance in cosmetology. We envision that VEGF165-myoblasts will provide better outcome than their non-tranduced counterparts. Myoblasts are not stem cells. Their competitive advantages over stem cells are presented.
Highlights
The human body consists of living cells supplied 100% with capillaries
Therapeutic angiomyogenesis, the concomitant regeneration of muscles and capillaries using biologics is the leading approach to combat these most eminent killers of mankind. This has already been achieved in animals with the unique platform technology of Vascular endothelial growth factor 165 (VEGF165)-myoblast transfer
Natural transcription of the normal genome within the donor nuclei following Myoblast Transfer Therapy (MTT) ensures orderly replacement of any protein deficiency resulting from single gene defect such as dystrophin for Duchenne muscular dystrophy (DMD), or from haphazard polygenic interactions such as GLUT4/IRAP for Type II diabetes
Summary
The human body consists of living cells supplied 100% with capillaries. More than 55% by volume of these cells are myogenic. Muscle degeneration is the common pathway of many fatal and debilitating diseases such as muscular dystrophies, heart failure, ischemic cardiomyopathy, Type II diabetes and aging disfigurement. Therapeutic angiomyogenesis, the concomitant regeneration of muscles and capillaries using biologics is the leading approach to combat these most eminent killers of mankind. This has already been achieved in animals with the unique platform technology of VEGF165-myoblast transfer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
